Web6 mrt. 2024 · Among patients receiving contemporary statins, inflammation assessed by high-sensitivity CRP was a stronger predictor for risk of future cardiovascular events and death than cholesterol assessed by LDLC. These data have implications for the selection of adjunctive treatments beyond statin therapy and suggest that combined use of … Web20 uur geleden · According to the researchers’ previous study, statin users can safely participate in a 12-week moderate-intensity exercise program that improves muscle function without causing muscle side effects. The results of this study support the results of previous studies. Medical Today Reporter Han Ji-hyeok ( [email protected])
Intensity of statin treatment after acute coronary syndrome, …
WebAlso, in those ≤75 years of age, a moderate intensity statin was recommended if a high-intensity statin therapy was contraindicated or if characteristics predisposing to statin-associated adverse effects were present. Thus, the goal for statin use in secondary prevention was maximally tolerated statin therapy that provided net benefit. Web9 jul. 2024 · Risk factors in relation to statin dose–intensity among patients with T2D, 2024. Discussion. The current study sought to provide an up-to-date data on statin prescription utilization for the primary prevention of CVD in subjects with T2D who had no history of … raymond siu ming wong
Table 5. Statin Dose Intensity and Equivalency Chart* - MQIC
Web17 feb. 2024 · Dosage and intensity: The typical pravastatin dosage range is 10 mg to 80 mg daily. The 10 and 20 mg doses are considered low intensity. And the 40 mg to 80 mg doses are considered moderate intensity. Ways to save: Pravastatin is available as a lower-cost generic. Prices are as low as $ 4.50 at certain pharmacies with a free GoodRx … Web19 jan. 2024 · Currently, there are only a few high intensity statins available in the U.S.: Atorvastatin (Lipitor) 40 mg. Atorvastatin (Lipitor) 80 mg. Rosuvastatin (Crestor) 20 mg. … Web4 sep. 2014 · A. There is no increased risk for NOD in anyone who begins statin therapy, regardless of baseline fasting blood glucose level. B. Everyone who starts statin therapy has the same increase in risk for NOD, regardless of baseline fasting blood glucose level. C. The risk for NOD is higher with high- compared with moderate-intensity statin therapy. D. raymond siu chak yee